Cyclerion Therapeutics (CYCN) presents a near-terminal liquidation posture as of March 31, 2026. Total assets of $8.5M consist primarily of: cash and equivalents of $2.8M (100% recoverable), a long-term equity investment of $5.35M carried as OtherLongTermInvestments (the 10% Tisento stake received in the 2023 zagociguat asset sale), net PP&E of $66K (minimal), and prepaid/other current assets of $266K. Intangibles carried at zero on the balance sheet; IP assets including MIT and Medsteer licenses have no assigned book value and receive a zero haircut under the liquidation lens. The Tisento equity interest is the single largest asset by book value but is a minority stake in a private, pre-revenue clinical-stage company with no observable market; recovery is uncertain and could be zero to a nominal fraction of $5.35M. Applying standard haircuts—cash at 100%, current assets at 90–95%, Tisento at indeterminate but likely deeply discounted value—gross liquidation recovery on the asset side is roughly $2.8M to $5M at best. Total liabilities are $1.7M (all current: AP $457K, accrued professional fees $984K, accrued compensation $21K, other current $104K), all settled at face value. No long-term debt, no pension obligations, no ASC 842 operating lease ROU assets or liabilities appear on the balance sheet, and the filing confirms no off-balance-sheet arrangements. Net equity book value is $6.8M; accumulated deficit stands at $274.2M. Liquidation value to equity under a stressed scenario (Tisento at zero) yields approximately $1.1M, consistent with MFFAIS CLV/LLV/OLV of $1.1M. Under an optimistic scenario where Tisento carries modest value, recovery could approach $3–4M, but this is speculative given the private, clinical-stage nature of that entity. The company has formally disclosed going concern doubt, with cash projected sufficient only through Q3 2026 absent the pending Korsana merger. The merger, announced April 1, 2026 (post balance sheet date), would result in current CYCN shareholders retaining approximately 1.5% of the combined entity on a fully diluted basis, with a CVR structure providing contingent rights to proceeds from legacy asset disposition (Akebia license, Tisento equity, other assets). The CVR structure is material to any liquidation scenario: it effectively means that if CYCN were wound down today absent the merger, the Akebia license milestones (up to $557.5M potential, zero probability-weighted near-term) and Tisento equity would be the residual value drivers. The filing discusses the Medsteer collaboration (January 2026) and MIT license (September 2025) in MD&A and footnotes but neither asset appears as a capitalized intangible in XBRL—both are expensed as incurred. The $1.0M Akebia Phase 2 milestone received in February 2026 is reflected in Q1 2026 cash flows as a reduction in accounts receivable ($1.0M decrease), not separately tagged as milestone revenue in the period's XBRL. Operating cash burn for Q1 2026 was $1.2M. At that run rate, the current $2.8M cash balance provides approximately two quarters of runway, consistent with the going concern disclosure.
▼ Community Notes